Skip to main content
SpringerLink
Log in

Anticancer Drug Resistance

Advances in Molecular and Clinical Research

  • Book
  • © 1994

Overview

Editors:
  1. Lori J. Goldstein

    1. Fox Chase Cancer Center, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Robert F. Ozols

    1. Fox Chase Cancer Center, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Treatment and Research (CTAR, volume 73)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Genetics of drug resistance

    • June L. Biedler, Barbara A. Spengler
    Pages 1-16

  3. P-glycoprotein homologues

    • Ellen Buschman, Pierre Lepage, Philippe Gros
    Pages 17-39

  4. The role of protein kinase C in multidrug resistance

    • Catherine A. O’Brian, Nancy E. Ward, Karen R. Gravitt, Dominic Fan
    Pages 41-55

  5. Transcriptional regulation of multidrug resistance gene expression

    • Snorri S. Thorgeirsson, Timothy W. Gant, Jeffrey A. Silverman
    Pages 57-68

  6. In vitro models of multiple drug resistance

    • Lee M. Greenberger, Dalia Cohen, Susan Band Horwitz
    Pages 69-106

  7. In vivo models of P-glycoprotein-mediated multidrug resistance

    • Michael M. Gottesman, Gerald H. Mickisch, Ira Pastan
    Pages 107-128

  8. Molecular diagnosis of multidrug resistance

    • Cynthia E. Herzog, Susan E. Bates
    Pages 129-147

  9. Clinical reversal of multidrug resistance

    • Branimir I. Sikic, George A. Fisher, Bert L. Lum, Nathalie A. Brophy, Anne M. Yahanda, Kent M. Adler et al.
    Pages 149-165

  10. Role of gene amplification in drug resistance

    • Patricia V. Schoenlein
    Pages 167-200

  11. Biochemical modulation as an approach to reversal of antimetabolite resistance

    • Peter J. O’Dwyer
    Pages 201-216

  12. Mechanisms of acquired resistance to cisplatin

    • Paul A. Andrews
    Pages 217-248

  13. Mechanisms of resistance to alkylating agents

    • O. Michael Colvin
    Pages 249-262

  14. Mechanisms of resistance to topoisomerase inhibitors

    • Allan Y. Chen, Leroy F. Liu
    Pages 263-281

  15. Back Matter

    Pages 283-294
    Download chapter PDF
Back to top

Keywords

About this book

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation.
Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated.
Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance.
It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.

Editors and Affiliations

  • Fox Chase Cancer Center, Philadelphia, USA

    Lori J. Goldstein, Robert F. Ozols

Bibliographic Information

  • Book Title: Anticancer Drug Resistance

  • Book Subtitle: Advances in Molecular and Clinical Research

  • Editors: Lori J. Goldstein, Robert F. Ozols

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-1-4615-2632-2

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1994

  • Hardcover ISBN: 978-0-7923-2836-0Published: 31 December 1994

  • Softcover ISBN: 978-1-4613-6129-9Published: 11 October 2012

  • eBook ISBN: 978-1-4615-2632-2Published: 06 December 2012

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XIII, 294

  • Topics: Oncology, Cancer Research, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation